Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors.
Souness
J E
JE
Discovery Biology 1 (JA3-1), Aventis Pharma Ltd., Dagenham Research Centre, Rainham Road South, Dagenham, RM10 7XS, Essex, UK. john.souness@aventis.com
Aldous
D
D
Sargent
C
C
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors* / Q000502:physiology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy*; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D003509:Cyclohexanecarboxylic Acids / Q000494:pharmacology / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy*; D009570:Nitriles; D010726:Phosphodiesterase Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D003509:Cyclohexanecarboxylic Acids; D003879:Dermatologic Agents; D009570:Nitriles; D010726:Phosphodiesterase Inhibitors; C433247:Cilomilast; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4